{
    "organizations": [],
    "uuid": "1ff1a735a836d88eda78c9c7d2259b4f6449a4dd",
    "author": "",
    "url": "https://www.reuters.com/article/brief-exelixis-announces-updated-phase-1/brief-exelixis-announces-updated-phase-1-trial-results-for-cabozantinib-idUSASB0C4GH",
    "ord_in_thread": 0,
    "title": "BRIEF-Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 15 PM / Updated 8 minutes ago BRIEF-Exelixis Announces Updated Phase 1 Trial Results For Cabozantinib Reuters Staff 1 Min Read \nFeb 7 (Reuters) - Exelixis Inc: \n* EXELIXIS ANNOUNCES UPDATED PHASE 1 TRIAL RESULTS FOR CABOZANTINIB IN COMBINATION WITH NIVOLUMAB WITH OR WITHOUT IPILIMUMAB IN REFRACTORY GENITOURINARY (GU) TUMORS Source text for Eikon:  ",
    "published": "2018-02-07T15:14:00.000+02:00",
    "crawled": "2018-02-07T15:35:38.025+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "announces",
        "updated",
        "phase",
        "trial",
        "result",
        "cabozantinib",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "exelixis",
        "inc",
        "exelixis",
        "announces",
        "updated",
        "phase",
        "trial",
        "result",
        "cabozantinib",
        "combination",
        "nivolumab",
        "without",
        "ipilimumab",
        "refractory",
        "genitourinary",
        "gu",
        "tumor",
        "source",
        "text",
        "eikon"
    ]
}